Literature DB >> 29891462

[Association of plasma level of advanced oxidation protein products with Framingham risk score in type 2 diabetic patients without vascular diseases].

Chao Xie1, Jie Tian, Wei Li, Min Liang, Yao-Zhong Kong.   

Abstract

OBJECTIVE: To explore the association of plasma level of advanced oxidation protein products (AOPPs) with Framingham risk score in type 2 diabetic patients without vascular diseases. METHDOS: This cross-sectional study was conducted among type 2 diabetic patients without vascular diseases recruited from 3 affiliated hospitals of Southern Medical University between March, 2010 and May, 2011, with age- and gender-matched healthy individuals as the control group. The demographic data were collected from all the participants, and the biochemical indexes and plasma levels of AOPPs were examined. The risk of cardiovascular disease in 10 years was assessed for all the participants based on their Framingham risk scores.
RESULTS: A total of 112 diabetic patients and 49 healthy subjects were enrolled in this study. The diabetic patients had significantly higher body mass index (BMI), blood glucose, triglyceride, low-density lipoprotein (LDL), plasma AOPPs and Framingham risk score but lower high-density lipoprotein level than the control subjects. Spearman correlation analysis showed that plasma level of AOPPs was positively correlated with the Framingham risk score (r=-0.44, P<0.001), and further multiple linear regression analysis suggested that plasma AOPPs level was independently correlated with the Framingham risk score (β0.305, P<0.001).
CONCLUSION: Type 2 diabetic patients without vascular diseases have significantly higher plasma levels of AOPPs and are at a greater risk of cardiovascular events in 10 years than healthy individuals. Plasma AOPPs are positively correlated with the Framingham risk score, suggesting the value of plasma AOPPs level in predicting the risk of cardiovascular events in these patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29891462      PMCID: PMC6743899     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  20 in total

Review 1.  The Characteristics and Roles of Advanced Oxidation Protein Products in Atherosclerosis.

Authors:  Hanxiao Ou; Zhuping Huang; Zhongcheng Mo; Ji Xiao
Journal:  Cardiovasc Toxicol       Date:  2017-01       Impact factor: 3.231

2.  Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications.

Authors:  Diwesh Chawla; Savita Bansal; Basu Dev Banerjee; Sri Venkata Madhu; Om Prakash Kalra; Ashok Kumar Tripathi
Journal:  Microvasc Res       Date:  2014-06-28       Impact factor: 3.514

3.  Increased plasma advanced oxidation protein products is an early marker of endothelial dysfunction in type 2 diabetes patients without albuminuria 2.

Authors:  Min Liang; Jun Wang; Chao Xie; Yan Yang; Jian Wei Tian; Yao Ming Xue; Fan Fan Hou
Journal:  J Diabetes       Date:  2014-03-27       Impact factor: 4.006

Review 4.  [The advanced oxidation protein products as potential diagnostic and prognostic factor in diseases of the indicated participation of oxidative stress].

Authors:  Agnieszka Piwowar
Journal:  Postepy Hig Med Dosw (Online)       Date:  2014-05-08       Impact factor: 0.270

5.  AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus.

Authors:  Agnieszka Piwowar; Maria Knapik-Kordecka; Maria Warwas
Journal:  Diabetes Res Clin Pract       Date:  2007-03-01       Impact factor: 5.602

6.  Cardiovascular Disease Incidence and Risk Factor Patterns among Omanis with Type 2 Diabetes: A Retrospective Cohort Study.

Authors:  Abdul Hakeem Al Rawahi; Patricia Lee; Zaher A M Al Anqoudi; Ahmed Al Busaidi; Muna Al Rabaani; Faisal Al Mahrouqi; Ahmed M Al Busaidi
Journal:  Oman Med J       Date:  2017-03

7.  Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway.

Authors:  Zhi Jian Guo; Hong Xin Niu; Fan Fan Hou; Lu Zhang; Ning Fu; Ryoji Nagai; Xiao Lu; Bai Hong Chen; Yue Xin Shan; Jian Wei Tian; Ram H Nagaraj; Di Xie; Xun Zhang
Journal:  Antioxid Redox Signal       Date:  2008-10       Impact factor: 8.401

8.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

9.  Association between advanced oxidation protein products (AOPP) and vascular calcification in uremic patients.

Authors:  L Lin; G-J Zhao; L-L Qin
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-09       Impact factor: 3.507

10.  Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up study.

Authors:  Louise Gek Huang Goh; Timothy Alexander Welborn; Satvinder Singh Dhaliwal
Journal:  BMC Womens Health       Date:  2014-09-26       Impact factor: 2.809

View more
  1 in total

1.  Implications of advanced oxidation protein products and vitamin E in atherosclerosis progression.

Authors:  Leila Azouaou Toualbi; Adnane Mounir; Ballouti Wafa; Arab Medina; Khelfi Abderrezak; Toualbi Chahine; Chader Henni; Bennoui Abdelghani; Seba Atmane
Journal:  Arch Med Sci Atheroscler Dis       Date:  2021-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.